Research
Citi's Six-Stock SMid Biotech Note: Why the Buy-Buy-Buy-Buy-Buy-Neutral Pattern Is the Sector Inflection
Citi initiated coverage on six SMid biotechs last Monday. Five Buys. One Neutral. The pattern, not the targets, is the sector call long-only generalists missed.